Leora Horn

Vanderbilt University

Full Professor(heuristic)

Lung Cancer Treatments and Mutations · Pulmonary and Respiratory Medicine

h-index49

i10-index100

Publications276

Citations17,680

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 29

Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer
Nature Medicine · 2025-11-20
Supplemental Table 1 from Development, Review, and Activation of Thoracic Oncology Investigator-Initiated TrialsPreprint
2025-03-17
Data from Development, Review, and Activation of Thoracic Oncology Investigator-Initiated TrialsPreprint
2025-03-17
Supplemental Table 2 from Development, Review, and Activation of Thoracic Oncology Investigator-Initiated TrialsPreprint
2025-03-17
Supplemental Table 3 from Development, Review, and Activation of Thoracic Oncology Investigator-Initiated TrialsPreprint
2025-03-17
Supplemental Figure 1 from Development, Review, and Activation of Thoracic Oncology Investigator-Initiated TrialsPreprint
2025-03-17
Supplemental Table 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung CancerPreprint
2025-02-17
Supplemental Methods 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung CancerPreprint
2025-02-17
Data from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung CancerPreprint
2025-02-17
Supplemental Figure 6 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung CancerPreprint
2025-02-17
Supplemental Table 2 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung CancerPreprint
2025-02-17
Supplemental Figure 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung CancerPreprint
2025-02-17
Supplemental Figure 3 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung CancerPreprint
2025-02-17
Supplemental Methods 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung CancerPreprint
2025-02-17
Supplemental Table 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung CancerPreprint
2025-02-17
Supplemental Figure 6 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung CancerPreprint
2025-02-17
Supplemental Figure 4 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung CancerPreprint
2025-02-17
Supplemental Figure 5 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung CancerPreprint
2025-02-17
Supplemental Table 2 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung CancerPreprint
2025-02-17
Supplemental Figure 2 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung CancerPreprint
2025-02-17

Open author page on OpenAlex →